70 related articles for article (PubMed ID: 8346178)
1. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.
Visscher DW; Sarkar F; LoRusso P; Sakr W; Ottosen S; Wykes S; Crissman JD
Mod Pathol; 1993 May; 6(3):302-6. PubMed ID: 8346178
[TBL] [Abstract][Full Text] [Related]
2. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma.
Visscher DW; DeMattia F; Ottosen S; Sarkar FH; Crissman JD
Mod Pathol; 1995 Aug; 8(6):665-70. PubMed ID: 8532703
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic analysis of macrophage infiltrates in breast carcinoma.
Visscher DW; Tabaczka P; Long D; Crissman JD
Pathol Res Pract; 1995 Nov; 191(11):1133-9. PubMed ID: 8822115
[TBL] [Abstract][Full Text] [Related]
5. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
[TBL] [Abstract][Full Text] [Related]
6. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
7. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
8. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
9. Immunohistologic analysis of invasive phenotype in breast carcinoma. A clinicopathologic study.
Visscher DW; Sarkar FH; Sakr W; Crissman J
Pathol Res Pract; 1993 Sep; 189(8):867-72. PubMed ID: 8302708
[TBL] [Abstract][Full Text] [Related]
10. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
11. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
12. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus.
Torzewski M; Sarbia M; Verreet P; Dutkowski P; Heep H; Willers R; Gabbert HE
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2263-8. PubMed ID: 9815623
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
16. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Nielsen BS; Sehested M; Timshel S; Pyke C; Danø K
Lab Invest; 1996 Jan; 74(1):168-77. PubMed ID: 8569179
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Okusa Y; Ichikura T; Mochizuki H
Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
[TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]